Characteristics of patients diagnosed as non-allergic following food allergy oral immunotherapy referral.
Background: Ascribing food allergy diagnosis to patients who are not allergic is well described, but its implications on oral immunotherapy (OIT) have not been studied. The aim was to study non-allergic patients referred for OIT. Methods: All patients who began OIT at Shamir Medical Center between November 2015 and August 2020 were included. Medical records were reviewed, […]
Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy: a randomised placebo-controlled study.
Background: For young children with peanut allergy, dietary avoidance is the current standard of care. We aimed to assess whether peanut oral immunotherapy can induce desensitisation (an increased allergic reaction threshold while on therapy) or remission (a state of non-responsiveness after discontinuation of immunotherapy) in this population. Methods: We did a randomised, double-blind, placebo-controlled study in five […]
Peanut allergy: Beyond the oral immunotherapy plateau.
Background: There are a lack of disease-modifying treatments for peanut allergy, which is lifelong in most instances. Oral immunotherapy has remained at the forefront of prospective treatments, though its efficacy is consistently undermined by the risk of adverse reactions and meager sustained effects. Aim: This review discusses the current state of oral immunotherapy, its strengths […]
Oral immunotherapy: The answer to peanut allergy?
Peanut and tree-nut allergies have increased dramatically in prevalence, especially in children. Historically, children with food allergies have been treated through strict avoidance of the allergen. Recently, an oral preparation of peanut allergen (Palforzia) was approved for immunotherapy (ie, desensitization) in children 4 to 17 years old. This article reviews oral immunotherapy and its role […]